City

Beijing (1)

Overall Status

Completed (1)

Not yet recruiting (1)

Sign in for free

Phase

n/a (1)

phase 2 (1)

Sponsor

Peking University Cancer Hospital & Institute (1)

Peking University People's Hospital (1)

Collaborator

Intervention

camrelizumab (1)

cisplatin (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

pathological response

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting

Melanoma
+6 more

Camrelizumab

(no location specified)

Aug 21, 2022

Event-free Survival, Overall Survival, Local-recurrence Free Survival Trial in Beijing (Cisplatin)

Completed

Event-free Survival
+3 more

Cisplatin

Beijing, Beijing, China

Peking University People's Hospital

Jan 2, 2021